Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/16/2025

Management of Irregular Bleeding Associated with Depot Medroxyprogesterone Acetate (DMPA) Use

Initial Assessment and Treatment Approach

  • The Centers for Disease Control and Prevention (CDC) recommends evaluating for underlying gynecological problems such as interactions with other medications, sexually transmitted diseases, pregnancy, or pathologic uterine conditions before initiating treatment for irregular bleeding after DMPA injection 1, 2
  • If an underlying gynecological problem is identified, the CDC advises treating the condition or referring for care 2
  • The CDC notes that bleeding irregularities are common with DMPA use and generally not harmful 2, 3

Treatment Options for Irregular Bleeding

  • The CDC recommends NSAIDs for short-term treatment (5-7 days) as first-line treatment for unscheduled spotting or light bleeding 2, 4
  • For heavy or prolonged bleeding, the CDC suggests NSAIDs for short-term treatment (5-7 days) as first-line treatment, and hormonal treatment with low-dose combined oral contraceptives or estrogen for short-term treatment (10-20 days) if NSAIDs are ineffective 2, 4
  • The CDC advises that amenorrhea does not require medical treatment, but reassurance should be provided, and pregnancy should be ruled out if clinically indicated 2, 5

Patient Counseling and Education

  • The CDC recommends providing counseling about potential changes in bleeding patterns before DMPA initiation, and reassuring patients that unscheduled spotting or light bleeding is common, especially during the first 3-6 months of use 2, 3
  • Enhanced counseling about expected bleeding patterns and reassurance that these irregularities are generally not harmful has been shown to reduce DMPA discontinuation in clinical trials 3